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ABSTRACT (Maximum 200 Words)
The quantity of available eukaryotic Initiation Factor 4E (eIF4E) in cells plays a critical role in the regulation of protein synthesis. EIF4E overexpression has been found in human malignancies Nathan, 1997) . Furthermore, there appears to be an association of eIF4E overexpression and clinical outcomes ; Nathan, 1997; Li, 2001) .
The purpose of the study is to determine if high eIF4E overexpression (>7-fold increase) in patients with node negative breast cancer is associated with a statistically significant increased risk (2.5-fold) for cancer recurrence when compared to patients with low eIF4E overexpression. The study involves 255 patients treated with definitive local therapy (i.e. breast conservation therapy or modified radical mastectomy) and offered systemic adjuvant therapy per standard of care.
The cancer specimens are quantified for eIF4E overexpression by Western blot analysis. Each patient undergoes identical clinical surveillance. Initial clinical stage, eIF4E overexpression, and clinical outcomes data are coded and researchers are blinded until data analysis at the end of the study. The primary endpoint measured is breast cancer recurrence; local, regional and/or distant. The projected study accrual time is 3 years, with targeted study completion in 5 years.
To date 142 patients have been accrued, 133 patients have cancer specimens quantified for eIF4E level. In an interim analysis of 111 patients, in patients with the highest tertile of eIF4E level (> 14-fold), the relative risk for cancer recurrence was 6.2 x that of the low eIF4E group (<7-fold) (p=0.026). 
INTRODUCTION
Eukayotic Initiation Factor 4E (eIF4E) plays an important role in the regulation of protein synthesis of mRNA with long or complex 5'UTRs (untranslated regions),,2 3,A. It is elevated in breast cancer specimens, but not in normal breast tissue from non-cancer patients5,6. Preliminary retrospective study had suggested that the degree of elIF4E protein elevation may have prognostic significance, independent of T (size) or N (nodal) stage 7 . Given the limitations of small, retrospective studies, a prospective study of women with stage I to IIII breast carcinoma was carried out. The degree of eIF4E elevation was evaluated as an independent predictor for cancer recurrence. An interim analysis of this NCI-funded study was published and is attached as Appendix A.
As noted, high eIF4E elevation appeared to predict disease recurrence independent of nodal disease. However, neither studies were specifically designed to address whether eIF4E elevation is associated with breast cancer recurrence in node negative patients. The current project funded by the DAMD17-99-1-9256 is targeted to examine 255 patients with node negative breast cancer treated in the standard fashion (i.e. modified radical mastectomy or lumpectomy, axillary dissection, plus radiation) and offered systemic adjuvant therapy when appropriate. Tumor specimens collected at surgery are verified by the study pathologist. eIF4E levels are determined by Western blot analysis. The clinical data and outcomes of patients are collected based on a standardized follow-up protocol. The data are stored in a coded database with the researchers "blinded" until final analysis at the end of the study period. The standardized follow-up protocol includes physical examination every three months, annual mammograms, chest x-ray, and blood work (blood count and liver function tests) for years 0 to 3 after treatment, and biannual examinations thereafter. Any abnormalities will be examined and tissue diagnosis for recurrence will be documented. The endpoint of the study is to detect cancer recurrence, local (e.g. same breast), regional (e.g. same axilla), and/or distant metastasis. The intent of this study is to detect a statistically significant 2.5-fold increase in risk for cancer recurrence in patients with high eIF4E protein elevation compared to patients with low eIF4E protein elevation in a prospective study. Identify and recruit 255 patients for study b.
BODY
Codify and enter pre-treatment clinical data c.
Treat breast cancer in accordance with standard of care d.
Codify, perform and record T stage, ER/PR status, and treatment received e.
Periodic quality review (every 3 months) of clinical data base f.
Integrate patients into our follow-up network to increase compliance with the study protocol Update on Task 1 One hundred and eighty-one (181) patients with node negative breast cancer were accrued. One hundred and forty-two (142) of these patients meet all of the study inclusion and exclusion criteria. Thirty-nine were withdrawn, the majority for lack of adequate specimens for eliF4E assay. The target sample size is 255 patients. Patient accrual rate amongst eligible patients continues at >90% at LSU Heath Sciences CenterShreveport, and at about 80% at the E.A. Conway Hospital. Pre-operative clinical data, pathologic staging, and type of treatment have been collected and updated every three months. The data have been coded and stored in a secured database. As shown, of the 133 specimens tested, 43 specimens were noted to have elF4E elevation less than 7-fold. 90 cancer specimens have eIF4E elevation > 7-fold. Of those specimens with less than 7-fold elevation, the mean degree of protein elevation is 4.4+1.5 fold (mean+standard deviation). Of the specimens that were >7-fold elevated, the mean degree of elevation was 14.5+5.8-fold. The proportion and degree of high versus low elIF4E elevation in cancer specimens are consistent with that reported in previous studies5.7. Clinic visits by study patients per study calendar (Addendum H), i.e. 1. every 3 months (q 3 months) year 0-3 2. every 6 months years 4 and 5 3. annually thereafter b.
Clinical data base to be collected on follow-up to include: 1. symptoms and/or findings that are noted on complete history and physical examination 2.
annual mammography 3.
annual chest x-ray 4.
annual blood work (complete blood work and liver function test)
5.
any additional imaging studies to verify symptoms or abnormal findings 6.
any histology/cytology of biopsies performed c.
The primary endpoint to be measured is cancer recurrence (see definition in proposal) -all suspicious lesions identified by imaging or at clinic visits must be confirmed histologically (biopsy) or cytologically (needle aspirate) d.
Periodic review by data coordinator and PI to ensure compliance by study patients and investigators to study protocol (every 3 months)
Update on Task 3 Clinical follow-up data obtained per protocol, including physical examination, blood work, and radiologic imaging where applicable, have been updated for all 142 participants of the study. There have been 39 withdrawals from the study. Reasons for withdrawal are: 1) 20 patients with inadequate specimens for eIF4E assay 2) 6 specimens represented ipsilateral breast recurrence after initial BCT 3) 9 were inconclusively staged 4) 4 declined definitive therapy There has not been any study associated complications. Final analysis of clinical and molecular data to determine if high eIF4E overexpression predicts a statistically significant increase in cancer recurrence in node negative patients b.
Manuscript preparation
Update on Task 5
This is the third year of the study. As such, final analysis will not be performed until target accrual and median follow-up have been achieved. had breast cancer recurrences (P = .03, log-rank test), of 4E (eIF4E), a 25-kd cap-binding protein involved in the whom 11 died from the disease (P = .04, log-rank test). In initiation of protein synthesis, is one such potential molecthe group with low eIF4E overexpression (defined as less ular marker of cancer progression. 12-14 than sevenfold), one cancer recurrence was detected. eIF4E is a subunit of eIF4F, the purported "RNA heliHowever, inherent biases in small, retrospective studies case" complex that unwinds mRNAs with long 5'-untransare well documented. 2 4 ' 2 5 Thus, to verify and confirm our lated regions (5' UTRs). 4 - 6 Specifically, eIF4E binds to the initial observations, as well as to test our hypothesis that 7-methyl guanosine molecule (m7GpppN) of mRNAs, faeIF4E protein elevation predicts a worse clinical outcome in cilitating the attachment of elF4F and the subsequent bindpatients with stage 1 to 3 breast carcinoma, we designed a ing by the 40s ribosomal subunit. This allows for the initistudy with the following objectives: to prospectively accrue ation of protein synthesis. eIF4E level in cancer specimens, to ensure compliance with are short (<200 nucleotides). 4 Thus, mRNAs with long 5' a standardized breast cancer treatment protocol, to maintain UTRs account for only about 10% of all mRNAs. Under a standardized clinical follow-up protocol to detect cancer normal cellular conditions, mRNAs with short 5' UTRs, and recurrence and cancer-related death, and to determine thus less steric hindrance, outcompete mRNAs with long 5' whether a high e.F4E level portends a worse clinical UTRs for protein synthesis. Indeed, mRNAs with long 5' outcome. UTRs are in effect "translationally repressed."'14"1 5 The binding of eIF4E to mRNAs with long 5' UTRs increases METHODS the likelihood of binding by the RNA helicase (eIF4F) and One hundred ninety-one patients with stage I to 3 breast subsequent initiation of translation. eIF4E is the rate-limitgreaction. 7 " 6 Thus, an abuncancer were accrued prospectively in this institutional reian component in ti b indi leadstview board-approved study. All patients were treated with dance or overexpression of eliF4E leads to an increased deiivesrcathap(i.,m ifdrdclmselikelihood that mRNAs with long 5' UTRs will be definitive surgical therapy (i.e., modified radical mastectranslaed.w 4 tomy or breast conservation therapy and adjuvant radiation therapy) with curative intent. Systemic adjuvant therapy Some of the gene products upregulated by eIF4E over-(chemotherapy and/or hormonal therapy) was offered as per expression include cyclin Dl10 and c-myc,1 7 important in standard of care for the stage of disease. A standardized cell-cycle regulation; ornithine decarboxylase,1 important posttreatment clinical follow-up protocol was strictly adin bioamine synthesis; and two angiogenic factors, basic hered to: history and physical examinations every 3 months fibroblast growth factor (FGF-2)'I and vascular endothelial for the first 3 years, then every 6 months thereafter until year growth factor (VEGF).' 9 In addition, a mammalian Tousled-5, then annual visits for the lifetime of the patient. In like kinase (TLKIB) has been reported to be upregulated by addition, annual mammograms, blood work (complete eIF4E overexpresssion.20 This results in the phosphorylation of blood count and liver function tests), and chest radiographs histone H3 and confers radioresistance to transfected cells.
KEY RESEARCH ACCOMPLISHMENTS
were performed. Additional imaging and other diagnostic In vitro models have shown that transfection of cell lines tests were directed by abnormal findings. The primary endsuch as Chinese hamster ovaries (CHO), HeLa, and cloned points measured were disease recurrence (local, regional, rat embryo fibroblasts (CREF) by viral vectors with eIF4E systemic) and cancer-related deaths. overexpression result in the acquisition of malignant pheFrom each patient, at the time of primary surgical internotype.1 2 "1 6 "1 7 This malignant phenotype is manifested by vention, a fresh piece of tumor specimen of at least 100 mg loss of contact inhibition, acquisition of anchorage-indepenwas obtained. This was identified and verified by the study dent growth, and increased cell division. Conversely, when pathologist (F.A.). The specimen was immediately frozen in eIF4E overexpression is inhibited using antisense oligonuliquid nitrogen and stored at -70'C. A code was given to cleotides to eIF4E, the acquired malignant phenotype is each specimen at the time of collection for tracking purreversed. poses. One set of note cards, accessible only to the principal In addition, several malignant breast cell lines have been investigator, linked the specimen code with the patient data. shown to have eIF4E overexpression.1 3 Kerekatte et a1 22 To avoid inadvertent bias, the study pathologist, the invesfirst reported that elF4E was overexpressed in human breast tigators involved in the assay for eIF4E and other tumor carcinoma but not in benign breast specimens. We reported markers, and the data coordinator were unaware of patients' in a small retrospective study that the degree of eIF4E data sets. 22 ' 23 Briefly, protein lysate from each breast PR results were reported based on the degree and intensity specimen was prepared using 10 mg tissue cut into tiny of nuclear staining for all receptors respectively, with a pieces, suspended in 0.5 mL RIPA buffer (150 mmol/L positive result defined as greater than 10% staining. HERNaCl; 1% NP-40; 0.5% DOC; 0.1% SDS; 50 mmol/L Tris 2/neu slides were evaluated using the Hercep program [pH 8.0]; 0.1 mmol/L PMSF) and mechanically macerated (Dako Corp., Carpinteria, CA), with a positive result deusing a Savant Bio 101 Fastprep FP120 system (Savant fined as 2 or more. Instruments, Inc., Holbrook, NY). The macerate was then Survival and disease-free survival analysis were percentrifuged (10,000g for 10 minutes at 4'C), and the conformed using the Kaplan-Meier method and the log-rank centration of protein suspension was determined using the test. The Fisher exact test was used to determine eIF4E BCA protein assay kit (Pierce, Rockford, IL) against a protein elevation in relation to other known prognostic standard graph of known BSA protein concentrations.
markers. The Cox proportional hazard model was used to Equal amounts of protein lysate from each breast specitest for eIF4E as an independent prognostic marker and to men (20 p1g diluted in 1:10 RIPA) were separated using 4% determine the relative risk for cancer recurrence and cancerto 20% denaturing gel Tris-HC1 polyacrylamide gel elecrelated death. trophoresis. The proteins were then electroblotted onto a nylon membrane (Immobilon PVDF, Millipore, Bedford, RESULTS MA), and the membranes were blocked in 5% nonfat milk for 1 hour. Primary incubation of the membrane was then
The clinical data and the pathologic features of the speccarried out using a 1:500 dilution monoclonal mouse antiimens from the 191 patients with stage 1 to 3 breast cancer eIF4E antibody (Transduction Laboratories, San Diego, are summarized in Table 1 . The median age was 52 years. CA). Secondary incubation of the membrane was then carForty-nine patients underwent breast conservation therapy ried out using a 1:1,000 dilution of goat-antimouse horseand 142 underwent modified radical mastectomies. Eleven radish peroxidase conjugate. The blot was then developed percent of patients had T3 lesions, 45.5% had T2 lesions, using Opti 4CN (4-chloro-1-naphthol, Bio-Rad Laboratoand 43.5% had T1 lesions. Most tumors were grade 2 or ries, Hercules, CA). The blots were scanned using the higher, and 46.6% had nodal involvement. For patients Biophotonics system (Biophotonics Corp., Ann Arbor, MI) whose specimen receptor status was available, 48.7% were and band intensity was evaluated using Intelligent Quanti-ER positive, 40% were PR positive, and 30.3% were HERfier software (Bio Image, Ann Arbor, MI). 21neu positive. The median follow-up of the study is 19 The quantification of eIF4E levels in each cancer specimonths. To date, 27 patients have had cancer recurrences, men was performed using two standards. The degree of 15 of whom have died from the disease. eIF4E elevation is expressed as the number of folds over eIF4E protein level was determined using Western blots. protein lysate controls of breast specimens from patients As in previous studies, eIF4E protein level in cancer specwithout cancer. In addition, on the same blot, a standard imens was quantified relative to benign specimen controls curve of a known concentration of eIF4E protein was used from patients without cancer as the number of folds over the to internally verify the quantification process (Fig. 1 ). Tripbaseline eIF4E level. A typical Western blot for eIF4E licates of each specimen were run and the results averaged.
overexpression is shown in Figure 1 . eIF4E overexpression Immunohistochemical staining for estrogen receptor is readily shown by the higher intensity of the eIF4E band (ER), progesterone receptor (PR), and HER-2/neu was perin the carcinoma specimens (lanes CA-1 to CA-5), even formed on a Dako Autostainer (Dako Corp., Carpinteria, after a 1:10 dilution of the protein lysate. In contrast, undi-CA) using standard protocols. Slides were evaluated using luted protein lysate from a benign specimen of a patient Duration follow-up, months low group. This was also statistically significant (P = .003, Median = 19 months log-rank test).
Range 1-125 months Multivariate Cox proportional hazard analysis was performed where nodal status, tumor size, tumor grade, ER status, and PR status were considered together with eIF4E without cancer is shown in the last lane. This band is used protein elevation in predicting cancer recurrence. As shown as a baseline control for the quantification of eIF4E elevain Table 3 , nodal status (P = .01) and high eIF4E protein tion. An eIF4E antigen standard curve is also shown (lanes overexpression (P = .019) were independent predictors of 2-4). disease recurrence. In the cancer specimens tested, eIF4E protein was ele-
The relative risk for cancer recurrence for high and invated between 1.9-fold and 48.4-fold over benign controls.
termediate eIF4E protein elevation versus low eIF4E was The mean (± SD) elevation of eIF4E protein in cancer calculated. The intermediate group had 4.1 times the risk for specimens was 12.2 ± 7.8-fold. Based on the degree of eIF4E elevation, patients were distributed into three similarly proportioned groups or tertiles. In group 1, 64 patients Table 2 . eIF4E AND had low eIF4E elevation (<7.5-fold overexpression). In CLINICOPATHOLOGIC FEATURES group 2, 61 patients had intermediate eIF4E levels (7.5-to 14-fold elevation). In group 3, 66 patients had high eIF4E P Value (Fisher exact test) elevation (>14-fold overexpression). The tertile distribu- cancer recurrence compared with the low group (P = .037, ized breast cancer treatment protocol, to maintain a stan-95% confidence interval [CI], 1.09-15.6)) ( Table 4 ). In the dardized clinical follow-up protocol to detect cancer recurhigh group, the relative risk for cancer recurrence was 7.2 rence and cancer-related death, and to determine whether a times that of the low group (P = .002, CI 2.08 -24.8).
high eIF4E level predicts a worse clinical outcome. The relative risk for cancer-related death was also examOne hundred ninety-one patients with stage 1 to 3 breast ined. The intermediate group had a relative risk of 4.1 times cancer were accrued. All of the patients were treated with that of the low group. This has not reached statistical standard surgery (breast conservation therapy with radiation significance yet (P = .091, CI 0.797-21.4) ( Table 5 ). In the therapy or modified radical mastectomy) and adjuvant therhigh group, the relative risk for cancer-related death was 7.3 apy. A standardized clinical follow-up protocol to detect times that of the low group. This was statistically significant recurrent disease was strictly adhered to. Compliance with (P = .011, CI 1.58-33.9).
treatment and follow-up exceeded 95%.
The patients were distributed into tertiles based on eIF4E DISCUSSION protein elevation: low elF4E elevation (<7.5-fold, n = 64
This study was undertaken to validate our initial obserpatients), intermediate eIF4E elevation (7.5-to 14-fold, n = vation that high eIF4E protein overexpression in cancer 61), and high eIF4E elevation (>14-fold, n = 66). The specimens of patients with stage 1 to 3 breast cancer had a relative risk for cancer recurrence in the intermediate group significantly higher rate of cancer recurrence and cancerwas 4.1 times that of the low group (P = .037). For the high related death. The initial study was small and retrospective; group, the relative risk for cancer recurrence was even as such, inherent biases may have included variability in higher, at 7.2 times that of the low group (P = .002). The treatment compliance, follow-up for disease recurrence, and relative risk for cancer-related death for the high group was false-positive results. Thus, this study was designed with the 7.3 times that of the low group (P = .01). following objectives: to prospectively accrue patients with
The clinical follow-up for this study is short: the median stage 1 to 3 breast cancer, to quantify cancer specimen follow-up is 19 months. Nonetheless, the patients with high elF4E level, to ensure patient compliance with a standardeIF4E levels have consistently shown a significantly higher
1.0
Low eIF4E
Intermediate eIF4E -0.6 c Figure 4 . 27 In light of the cancer recurrence, but not cancer-related death yet.
reported association of eIF4E overexpression and the upeIF4E elevation as a marker for cancer recurrence has regulation of two potent angiogenic factors (VEGF and been reported in other solid tumors. Nathan et a1 26 reported FGF-2) in vitro18,19 and the increased relative risk for canthat eIF4E elevation in the tumor-free margins of squamous cer recurrence in patients with high elF4E that is indepencell carcinoma of the head and neck after curative resection dent of nodal disease, the potential of eIF4E as a marker for was associated with an increased cancer recurrence rate. In hematologic dissemination is especially intriguing. that study, patients with eIF4E elevation detected in the In our laboratory, we have preliminary data showing that tumor-free surgical margins had a cancer recurrence rate of eIF4E overexpression is associated with the upregulation of 56%. In contrast, when eIF4E elevation was absent, the VEGF in human breast cancer specimens (manuscript in recurrence rate was 6.9% On multivariate analysis, eIF4E preparation). In addition, VEGF and FGF-2 upregulation elevation at the margins persisted as an independent proghas been associated with increased microvessel density. 2 8 3°n ostic marker for cancer recurrence (P. -.009).
Further, an increase in microvessel density and a worse clinical Efforts at identifying prognostic markers in breast cancer outcome for breast cancer has been observed. linkage of high eIF4E overexpression, resulting in angiogenic When eIF4E level was analyzed relative to tumor size, factors upregulation, subsequent increase in tumor microvessel tumor grade, nodal status, ER status, PR status, HER-2lneu density, and a worse clinical outcome may exist. Thus, the status, and menopausal status, high eIF4E level was assopotential of elF4E as an early marker of risk for hematogenous ciated with high tumor grade (P = .019), PR-positive tumor dissemination, independent of nodal disease, needs further (P = .027), and node-positive disease (P = .028). In addiinvestigation. Studies on this potential linkage are underway. tion, on multivariate analysis, after adjusting for ER status, PR status, tumor size, tumor grade, nodal status, and meno-CONCLUSIONS pausal status, high eIF4E elevation continues to be a significant independent prognostic marker for cancer recurrence.
A high eIF4E level is an independent predictor of cancer The recent interest in the importance of hematologic recurrence in patients with stage 1 to 3 breast cancer. The relative risk for cancer recurrence increases with eIF4E protein elevation. High eIF4E elevation is also associated with an increased relative risk for cancer-related death. has reached statistical significance compared to the low group. I think this Finally, I would ask you about the estrogen levels in these patients. I is due to the short median follow-up in this prospective study, being only think any future correlates should really look at the menopausal status and 19 months. I suspect that the intermediate group will eventually reach the absolute estrogen values, particularly in the follicular phase, days 1 statistical significance, as the P value currently is .09. through 13. Do you have any plans to look at that data? throgh 3. o yo hae ay plns o lok a tht dtaWith regards to your second question about node-negative disease, we I found this to be a most interesting paper. I am glad he brought it to the ha regars tec ond question abou t node-negative attention of the Association. I enjoyed the manuscript. And I congratulate the authors on a timely presentation.
breast cancer patients and clinical outcome relative to 4E elevation. That study is currently accruing patients. As you might expect, node-negative DR. GERARD M. DOiERTY (St. Louis, MO): Congratulations on a very patients' recurrences will take a little longer, so I don't think we will have nice prospective validation of your previous observations. I think the fact mature data for another 4 or 5 years. that this is prospective is very important. I have two quick questions for
We did look at menopausal status, and it did not predict recurrence. I did you.
not look at the degree of ERIPR as a predictor of whether the outcome may One, have you done immunohistochemistry to look at eIF4E 40 levels, be affected by eIF4; I think that is a wonderful idea. A lot of these ER and are these differences detectable that way? I don't think our pathologists receptor data were obtained by immunohistochemical staining. are going to do quantitative Western blotting with the same facility that you Dr. Doherty, we have looked at immunohistochemical staining for 4E. In have, for us to be able to translate this into clinical prognostic use.
fact, if you look at IHC slides, and we have presented IHC data at other The second thing is that you seem to have identified an important meetings, 4E is highly overexpressed in the infiltrating ductal carcinoma pathway in the aggressiveness of these breast cancers. While prognosis and but not in the surrounding tissue. However, as you well know, quantificabiomarker information is great, what we really want is better treatments.
tion by immunohistochemical techniques is much more challenging. We Have you speculated about how you might use this information about the have used a number of systems to try to quantitate IHC for 4E, and we have overexpression of eIF4E and maybe a competitive advantage for translation of these long terminal repeat proteins in the cancer patients? Is there not had the same r odbi l th oHC as itst blots. some way you can inhibit that activity?
Finally, how is this going to be helpful to our patients? Low 4E elevation as a prognostic marker may identify a subset of patients that do not need DR. BENJAMIN D. L. Li (Shreveport, LA): Thank you for the kind chemotherapy. Therapeutically, my colleagues in molecular biology have comments and very insightful questions.
been working on a gene construct with a long 5' UTR that exploits cancer Dr. Bland, we have analyzed 4E levels as a continuum and in discrete cells with overexpression of 4E. The same construct allows for a suicidal data sets, as in high, intermediate, and low groups. The risk for cancer gene to be factor transfected into cancer cells. Since cancer cells overexrecurrence as well as for cancer death increa•es. with 4E elevation in press 4E, the suicide gene will be preferably expressed in cancer cells.
